Transcription of Data Sheet FORTEO - Medsafe
{{id}} {{{paragraph}}}
Example: marketing
Data Sheet FORTEO - Medsafe
FORTEO -ds-v 7. 0-28feb14 Page 1 of 13 data Sheet FORTEO teriparatide 250 microgram/mL, solution for injection Presentation Teriparatide (rhPTH(1-34)) is identical to the 34 N-terminal amino acid sequence of endogenous human parathyroid hormone, and is manufactured using recombinant DNA technology. FORTEO 250 microgram/mL solution for injection is supplied as a mL cartridge contained in a prefilled disposable delivery device (pen). FORTEO 250 microgram/mL solution is a sterile, colourless, clear, isotonic solution intended for subcutaneous injection. The pen delivers 20 microgram per dose and contains dosing for 28 treatment days. Uses Actions Endogenous 84-amino-acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. Physiological actions of PTH include stimulation of bone formation by direct effects on bone forming cells (osteoblasts), indirectly increasing the intestinal absorption of calcium and increasing the tubular re-absorption of calcium and excretion of phosphate by the kidney.
forteo-ds-v7.0-28feb14 Page 1 of 13 Data Sheet FORTEO® teriparatide 250 microgram/mL, solution for injection
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: